A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score

Lupón, Josep; Cediel, Germán; Moliner, Pedro; Antonio, Marta de; Domingo, Mar; Zamora, Elisabet; Núñez, Julio; González, Beatríz; Santiago‐Vacas, Evelyn; Santesmases, Javier; Troya-Saborido, Maria Isabel; Díez‐Quevedo, Crisanto; Boldo, M; Barallat, Jaume; Bayés‐Genís, Antoni

doi:10.1016/j.ijcard.2019.05.046

Cited by 18 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A single study of patients with coronary artery disease found that soluble ST2 and high-sensitivity troponin were associated with sudden cardiac death [80]. Two studies have found elevated soluble ST2 levels to be associated with sudden cardiac death in patients with both ischaemic and non-ischaemic heart failure [81,82], however, the utility of soluble ST2 to improve SCD prediction in DCM remains unexplored.…”

Section: Serological Markers Of Riskmentioning

confidence: 99%

Sudden Cardiac Death Prediction in Non-ischemic Dilated Cardiomyopathy: a Multiparametric and Dynamic Approach

Hammersley

Halliday

2020

Curr Cardiol Rep

View full text Add to dashboard Cite

Purpose of Review Sudden cardiac death is recognised as a devastating consequence of non-ischaemic dilated cardiomyopathy. Although implantable cardiac defibrillators offer protection against some forms of sudden death, the identification of patients in this population most likely to benefit from this therapy remains challenging and controversial. In this review, we evaluate current guidelines and explore established and novel predictors of sudden cardiac death in patients with non-ischaemic dilated cardiomyopathy. Recent Findings Current international guidelines for primary prevention implantable defibrillator therapy do not result in improved longevity for many patients with non-ischemic cardiomyopathy and severe left ventricular dysfunction. More precise methods for identifying higher-risk patients that derive true prognostic benefit from this therapy are required. Summary Dynamic and multi-parametric characterization of myocardial, electrical, serological and genetic substrate offers novel strategies for predicting major arrhythmic risk. Balancing the risk of non-sudden death offers an opportunity to personalize therapy and avoid unnecessary device implantation for those less likely to derive benefit.

show abstract

Section: Serological Markers Of Riskmentioning

confidence: 99%

Sudden Cardiac Death Prediction in Non-ischemic Dilated Cardiomyopathy: a Multiparametric and Dynamic Approach

Hammersley

Halliday

2020

Curr Cardiol Rep

View full text Add to dashboard Cite

show abstract

“…Для цитирования: Гаспарян А. Ж., Гусева Е. В., Тарасовский Г. С., Каштанова С. Ю., Уцумуева М. Д., Шарф Т. В., Миронова Н. А., Соколов С. Ф., Масенко В. П., Скворцов А. А., Шлевков Н. Б. Изучение динамики биомаркеров NT-proBNP и sST2 для прогнозирования одиночных желудочковых тахиаритмий и "электрического шторма" у больных с систолической сердечной недостаточностью и различными имплантированными устройствами. For citation: В подавляющем большинстве случаев механизмом, лежащим в основе внезапной сердечной смерти (ВСС), являются пароксизмальные желудочковые тахиаритмии (ЖТ): желудочковая тахикардия и фибрилляция желудочков [1,2]. Прогнозирование возникновения ЖТ, а особенно, так называемого явления "электрического шторма" (ЭШ) -трёх и более устойчивых приступов ЖТ в сут., тесно связано с возможностями предсказания случаев ВСС.…”

Section: отношения и деятельность: нетunclassified

“…Значимых различий между ис-следованными группами пациентов по характеру лекарственной терапии ХСН, включая прием бетаадреноблокаторов, антагонистов минералокортикоидных рецепторов, ингибиторов ангиотензинпревращающего фермента и антиаритмических препаратов (амиодарон), выявлено не было. В то же время груп- (6,8-7,5) 7,0 (6,5-7,6) 8,2 (7,(1)(2)(3)(4)(5)(6)(7)(8)6) КСР ЛЖ, см 6,1 (5,8) 6,0 (5,7-6,7) 7,5 (6,6) па "ЭШ" отличалась от двух других групп пациентов наибольшими значениями конечно-диастолического размера ЛЖ (8,2 (7,1-8,6) см) и конечно-систолического размера (КСР) ЛЖ (7,5 (6,9-7,6) см), р<0,05. Обращало на себя внимание отсутствие статистически значимых различий между всеми тремя группами больных по исходным значениям ФВ ЛЖ.…”

Section: результаты сравнительного анализа клинико-инструментальных пunclassified

Changes of NT-proBNP and sST2 levels for predicting isolated episodes of ventricular tachyarrhythmias and electrical storm in patients with systolic heart failure and various implanted devices

et al. 2020

View full text Add to dashboard Cite

“…Recently, growth stimulation expressed gene 2 (ST2) is a novel emerging biomarker for patient stratification in different clinical settings [12][13][14]. ST2 is a member of the Tollinterleukin 1 (IL-1) receptor superfamily that includes two unique proteins: truncated circulating soluble ST2 (sST2) and a membrane-bound form (lST2).…”

Section: Introductionmentioning

confidence: 99%

“…Further, increased levels of sST2 are correlated with more severe clinical symptoms and with other objective measures of HF severity such as higher C-reactive protein, higher natriuretic peptide levels, lower left ventricular ejection fraction (LVEF), and higher diastolic filling pressure [12,14,[19][20][21][22][23]. Using a nested case-control analysis of patients with ambulatory HF, Bayes-Genis and Giuseppe et al showed a significant correlation between elevated sST2 concentrations and risk of SCD [13,24]. In a recent study, Hicham et al also provided data on a biomarker substudy from the MADIT-CRT trial.…”

Section: Introductionmentioning

confidence: 99%

Circulating Soluble ST2 Predicts All-Cause Mortality in Severe Heart Failure Patients with an Implantable Cardioverter Defibrillator

Hou¹,

Yu²,

Gao³

et al. 2020

Cardiology Research and Practice

View full text Add to dashboard Cite

Background. Heart failure (HF) is the terminal stage of all cardiovascular events. Although implantable cardioverter defibrillator (ICD) therapies have reduced mortality among the high-risk HF population, it is necessary to determine whether certain factors can predict mortality even after cardiac device implantation. Growth stimulation expressed gene 2 (ST2) is an emerging biomarker for HF patient stratification in different clinical settings. Aims. This study aimed to investigate the relationship between baseline soluble ST2 (sST2) levels in serum and the clinical outcomes of high-risk HF patients with device implantation. Methods. Between January 2017 and August 2018, we prospectively recruited consecutive patients implanted with an ICD for heart failure, with LVEF ≤35% as recommended, and analyzed the basic characteristics, baseline serum sST2, and NT-proBNP levels, with at least 1-year follow-up. All-cause mortality was the primary endpoint. Results. During a 643-day follow-up, all-cause mortality occurred in 16 of 150 patients (10.67%). Incidence of all-cause mortality increased significantly in patients with sST2 levels above 34.98846 ng/ml (16.00% vs. 5.33%, P = 0.034 ). After adjusting the model (age, gender, device implantation, prevention of sudden death, LVEDD, LVEF, WBC and CLBBB, hsTNT, etiology, and eGFR) and the model combined with NT-proBNP, the risk of all-cause death was increased by 2.5% and 1.9%, respectively, per ng/ml of sST2. The best sST2 cutoff for predicting all-cause death was 43.42671 ng/ml (area under the curve: 0.72, sensitive: 0.69, and specificity: 0.69). Compared to patients with sST2 levels below 43.42671 ng/ml, the risk of all-cause mortality was higher in those with values above the threshold (5.1% vs. 21.2%, P = 0.002 ). ST2 level ≥43.42671 ng/ml was an independent predictor of all-cause mortality (HR: 3.30 [95% CI 1.02–10.67]). Age (HR: 1.06 [95% CI: 1.01–1.12]) and increased NT-proBNP per 100 (HR: 1.02 [95% CI: 1.01–1.03]) were also associated with all-cause mortality in ICD patients. Conclusions. sST2 level was associated with risk of all-cause mortality, and a threshold of 43.43 ng/ml showed good distinguishing performance to predict all-cause mortality in patients with severe heart failure, recommended for ICD implantation. Patients with sST2 levels more than 43.42671 ng/ml even after ICD implantation should therefore be monitored carefully.

show abstract

A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score

Cited by 18 publications

References 33 publications

Sudden Cardiac Death Prediction in Non-ischemic Dilated Cardiomyopathy: a Multiparametric and Dynamic Approach

Sudden Cardiac Death Prediction in Non-ischemic Dilated Cardiomyopathy: a Multiparametric and Dynamic Approach

Changes of NT-proBNP and sST2 levels for predicting isolated episodes of ventricular tachyarrhythmias and electrical storm in patients with systolic heart failure and various implanted devices

Circulating Soluble ST2 Predicts All-Cause Mortality in Severe Heart Failure Patients with an Implantable Cardioverter Defibrillator

Contact Info

Product

Resources

About